Generic Olumiant ( Baricitinib )

Buy Generic Olumiant (Baricitinib) without prescription in Canada

In our Canadian pharmacy, you can buy Olumiant (Baricitinib) without a prescription, with delivery across Canada within 5-14 days. Discreet and anonymous packaging.

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe rheumatoid arthritis, moderate to severe atopic dermatitis, and severe alopecia areata. It works by selectively inhibiting JAK1 and JAK2 enzymes, which are involved in the signalling pathways of multiple cytokines and growth factors that drive inflammation and immune responses. By blocking these pathways, baricitinib helps reduce joint pain and swelling, clear skin lesions, and promote hair regrowth, depending on the condition being treated.

Usual adult dose: The recommended dose is 4 mg taken orally once daily, with or without food. For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the dose is reduced to 2 mg once daily; it is not recommended in severe renal impairment (CrCl < 30 mL/min). Therapy should not be initiated in patients with an absolute lymphocyte count below 0.5 × 10⁹/L, absolute neutrophil count below 1 × 10⁹/L, or haemoglobin below 80 g/L. The tablet may be taken at any time of day, and routine laboratory monitoring is required before and during treatment.

Dosage form: Oral film-coated tablet, 4 mg. A 2 mg tablet is also available for dose adjustment.

Onset of action: For rheumatoid arthritis, clinical improvement may be seen as early as 2 weeks after starting therapy, with maximal benefit achieved by 12-16 weeks. In atopic dermatitis, itch reduction can occur within the first week, and significant skin clearance is often seen by 16 weeks. For alopecia areata, visible hair regrowth may take 8 to 12 weeks or longer.

Duration of action: The elimination half-life of baricitinib is approximately 12 hours, supporting once-daily dosing. The therapeutic effect persists as long as the drug is taken; upon discontinuation, symptoms of the underlying condition gradually return over weeks to months.

Alcohol recommendation: Alcohol consumption does not directly interfere with the action of Olumiant, but it should be limited. Heavy alcohol intake can increase the risk of liver damage, particularly in patients with pre-existing liver conditions or those taking other medications that affect the liver. Moderate consumption is generally acceptable.

Most common side effects: Upper respiratory tract infections (colds, sinusitis), nausea, herpes zoster (shingles), and increased liver enzymes. Blood tests may show an increase in cholesterol (hyperlipidaemia) and a decrease in certain blood cell counts. Serious risks include serious infections (such as pneumonia, tuberculosis, and fungal infections), venous thromboembolism (blood clots in the legs or lungs), major adverse cardiovascular events (heart attack, stroke), and malignancies (including lymphoma). A boxed warning outlines these risks. Baricitinib is not recommended in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs, or potent immunosuppressants.

Would you like to try Olumiant (Baricitinib) without a prescription?

General Information about Olumiant (Baricitinib)

• INN (International Nonproprietary Name): Baricitinib
• Brand names available in Canada: Olumiant® (Eli Lilly Canada Inc.) is the sole brand-name product. As of 2026, no generic versions are marketed in Canada.
• ATC code: L04AA37 (baricitinib; selective immunosuppressants, Janus-associated kinase (JAK) inhibitors)
• Dosage forms and strengths: Film-coated oral tablets: 2 mg and 4 mg. The 4 mg tablet is the standard dose for most indications.
• Manufacturers in Canada: Eli Lilly Canada Inc. (Olumiant).
• Registration status in Canada: Approved by Health Canada. Olumiant 4 mg received its Notice of Compliance on August 14, 2019, for rheumatoid arthritis; subsequent approvals were granted for atopic dermatitis (2021) and severe alopecia areata (2023). DIN: 02485931 (4 mg).
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Baricitinib is a reversible and selective inhibitor of Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. These enzymes are intracellular signalling molecules that transduce signals from multiple cytokine and growth factor receptors to the nucleus via the JAK-STAT pathway. By inhibiting JAK1 and JAK2, baricitinib blocks the signalling of many pro-inflammatory cytokines, including interleukins (IL-6, IL-12, IL-23), interferons (IFN-α, IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This action reduces the inflammatory and immune responses that drive the pathology in rheumatoid arthritis, atopic dermatitis, and alopecia areata. The drug has minimal activity against JAK3, which is involved in lymphocyte development and may contribute to a different safety profile.

After oral administration, baricitinib is rapidly absorbed, with peak plasma concentrations reached approximately 1 hour after dosing. Food does not significantly affect absorption. Baricitinib is approximately 50% bound to plasma proteins. It is a substrate of the renal organic anion transporter OAT3, but not a substrate of CYP450 enzymes, and undergoes minimal metabolism (less than 10%) mainly by CYP3A4. The elimination half-life is approximately 12 hours. About 75% of the drug is excreted unchanged in the urine, and the remainder in the faeces. Because of this extensive renal clearance, dose adjustment is required in patients with moderate renal impairment (creatinine clearance 30-60 mL/min); the 4 mg dose is reduced to 2 mg once daily. Baricitinib is not recommended in patients with severe renal impairment (CrCl < 30 mL/min).

Indications

• Rheumatoid Arthritis (RA): For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.
• Atopic Dermatitis (AD): For the treatment of adults with moderate to severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable. Olumiant can be used with or without topical corticosteroids.
• Severe Alopecia Areata (AA): For the treatment of severe alopecia areata in adults. Baricitinib promotes hair regrowth and was the first systemic therapy approved by Health Canada for this indication.
• Olumiant is not indicated for the treatment of psoriatic arthritis, ankylosing spondylitis, or other inflammatory conditions unless specified by a specialist. It should not be used in patients with active, serious infections, including tuberculosis, or in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine or cyclosporine.

Important Warnings and Precautions

At-risk groups

• Pregnancy: Baricitinib should not be used during pregnancy. Animal studies have shown reproductive toxicity. Women of childbearing potential must use effective contraception during treatment and for at least 1 week after the last dose. A pregnancy test should be performed before initiating therapy.
• Breastfeeding: It is not known whether baricitinib is excreted in human breast milk. Breastfeeding is not recommended during treatment. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics (< 18 years): Safety and efficacy in children and adolescents have not been established. Olumiant is not approved for use in paediatric patients.
• Elderly (≥ 65 years): No dose adjustment is required based on age alone. However, older adults are at increased risk of serious infections, cardiovascular events, and malignancies. In rheumatoid arthritis, the 4 mg dose may be used, but careful monitoring is essential. In atopic dermatitis and alopecia areata, the benefit-risk profile in patients over 65 has not been extensively studied; lower starting doses may be considered.
• Hepatic impairment: No dose adjustment is required in patients with mild to moderate hepatic impairment. Baricitinib has not been studied in severe hepatic impairment; use is not recommended.
• Renal impairment: In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the dose must be reduced to 2 mg once daily. Baricitinib is not recommended in patients with severe renal impairment (CrCl < 30 mL/min). Renal function should be assessed before and during therapy.
• Serious infections (Boxed Warning): Baricitinib increases the risk of developing serious infections that may lead to hospitalisation or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Active, serious infections, including tuberculosis (TB) and opportunistic infections, must be ruled out before starting therapy. If a serious infection develops, treatment should be interrupted until the infection is controlled. Patients should be closely monitored for signs and symptoms of infection during and after treatment.
• Tuberculosis: Patients should be screened for latent TB before initiating Olumiant; if positive, appropriate antimycobacterial therapy should be started before baricitinib is begun.
• Malignancies (Boxed Warning): Lymphoma and other malignancies have been reported in patients treated with JAK inhibitors. A higher rate of malignancies, including non-melanoma skin cancer, was observed in baricitinib-treated patients compared with tumour necrosis factor (TNF) inhibitor-treated patients in a large safety trial. Periodic skin examinations are recommended for patients at risk.
• Major Adverse Cardiovascular Events (MACE) (Boxed Warning): A higher rate of major adverse cardiovascular events, including myocardial infarction and stroke, was observed in baricitinib-treated patients with rheumatoid arthritis who were 50 years or older and had at least one cardiovascular risk factor, compared with TNF inhibitor-treated patients. Olumiant should be used with caution in patients with pre-existing cardiovascular risk factors, and the benefits should be weighed against the risks.
• Thromboembolic Events (Boxed Warning): Deep vein thrombosis and pulmonary embolism have been observed at an increased rate in baricitinib-treated patients compared with TNF inhibitors. Baricitinib should be used with caution in patients at risk for venous thromboembolism. If signs or symptoms of thrombosis occur, prompt evaluation is required, and treatment should be discontinued.
• Laboratory abnormalities: Baricitinib can cause dose-related increases in low-density lipoprotein (LDL) cholesterol, triglycerides, and liver transaminases (ALT/AST). It can also cause decreases in neutrophil counts (neutropenia), lymphocyte counts (lymphopenia), and haemoglobin. Complete blood counts, liver enzymes, and lipid profiles must be monitored before starting therapy and periodically thereafter. Treatment should not be initiated (or should be interrupted) if absolute lymphocyte count < 0.5 × 10⁹/L, absolute neutrophil count < 1 × 10⁹/L, or haemoglobin < 80 g/L.
• Vaccinations: Live vaccines should not be administered during or immediately prior to baricitinib therapy. All indicated vaccinations, including pneumococcal and influenza vaccines, should be brought up to date before starting treatment.
• Allergy: Do not take Olumiant if you have a known hypersensitivity to baricitinib or any excipient in the tablet.

Driving and alcohol

Olumiant is not known to impair the ability to drive or operate machinery. However, some patients may experience dizziness or fatigue, particularly during the initial weeks of therapy. Patients should determine their individual response before driving or performing hazardous activities. Alcohol should be consumed in moderation because heavy alcohol intake can contribute to liver enzyme elevations and may increase the risk of gastrointestinal side effects. There is no direct pharmacokinetic interaction between baricitinib and alcohol.

Dosage Instructions

• Rheumatoid arthritis, atopic dermatitis, severe alopecia areata (adults): The recommended dose is 4 mg taken orally once daily. The tablet should be swallowed whole with a glass of water and may be taken with or without food.
• Dose adjustment for renal impairment: In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the dose is reduced to 2 mg once daily. Baricitinib is not recommended in patients with severe renal impairment (CrCl < 30 mL/min).
• Dose adjustment for laboratory abnormalities: If absolute lymphocyte count falls below 0.5 × 10⁹/L or absolute neutrophil count below 1 × 10⁹/L, treatment should be interrupted. Once values return above these thresholds, therapy may be resumed at 2 mg once daily. If haemoglobin falls below 80 g/L, treatment should be interrupted and not restarted unless another cause is identified and corrected.
• Administration: Take the tablet at approximately the same time each day. Consistency helps maintain steady blood levels. If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.
• Duration of therapy: Olumiant is intended for long-term maintenance therapy. Treatment response should be assessed after 12-16 weeks; if no significant improvement is observed, discontinuation should be considered. In alopecia areata, response may require longer (up to 36 weeks) to fully evaluate.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Upper respiratory tract infections (nasopharyngitis, sinusitis), increased LDL cholesterol, and nausea.
• Common side effects (1-10%): Herpes zoster (shingles), urinary tract infection, elevated liver transaminases, thrombocytosis (increased platelets), headache, diarrhoea, and fatigue. Acne and folliculitis may occur, particularly in atopic dermatitis patients.
• Serious adverse reactions: Serious infections (including pneumonia, cellulitis, and reactivation of herpes zoster), venous thromboembolism (deep vein thrombosis and pulmonary embolism), major adverse cardiovascular events (myocardial infarction, stroke), malignancies (including non-melanoma skin cancer and lymphoma), gastrointestinal perforation (rare), hepatotoxicity, and neutropenia. Laboratory abnormalities include hyperlipidaemia, lymphopenia, neutropenia, and anaemia.
• Contraindications: Hypersensitivity to baricitinib or any excipient. Active, serious infections, including tuberculosis. Severe hepatic impairment (Child-Pugh C). Severe renal impairment (CrCl < 30 mL/min). Pregnancy and breastfeeding. Concomitant use with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine, cyclosporine).

Drug Interactions

• Other immunosuppressive therapies — avoid co-administration: Concurrent use of baricitinib with biologic DMARDs (e.g., TNF inhibitors, IL-6 receptor antagonists), other JAK inhibitors, or potent immunosuppressants such as azathioprine and cyclosporine may increase the risk of infections and other adverse effects. Baricitinib should not be used in combination with these agents.
• Methotrexate — no clinically significant interaction: Baricitinib can be used in combination with methotrexate without dose adjustment. Pharmacokinetic studies show no significant interaction.
• CYP3A4 substrates — potential interaction: Baricitinib is a weak inhibitor of CYP3A4. It may increase plasma concentrations of drugs metabolised by CYP3A4 with a narrow therapeutic index (e.g., cyclosporine, tacrolimus, and certain statins). Monitor for toxicity and adjust doses as needed.
• OAT3 substrates: Baricitinib is a substrate of OAT3 and may compete with other OAT3 substrates (e.g., cimetidine, probenecid). Concomitant use may increase baricitinib exposure. Caution is advised.
• Vaccines: Live attenuated vaccines (e.g., MMR, varicella, yellow fever) should not be administered during or shortly before baricitinib therapy. Inactivated vaccines may be given, but the immune response may be reduced.
• Alcohol and food: No clinically relevant food or alcohol interactions. Moderate alcohol consumption is acceptable.

Practical Advice

• Administration: Take Olumiant once daily with a glass of water, at the same time each day. The tablet may be taken with or without food. If you miss a dose, take it as soon as you remember on the same day; otherwise, skip it. Do not double the dose.
• Monitoring: Before starting treatment, your doctor will screen you for tuberculosis (TB), hepatitis B and C, and other infections. Blood tests are required to check your complete blood count (CBC), liver enzymes, and lipid profile. These tests should be repeated periodically (e.g., every 4-12 weeks initially, then every 3-6 months once stable). You should be alert for signs of infection, such as fever, cough, or skin lesions, and report them immediately. Skin examinations are recommended for early detection of skin cancer, especially if you have risk factors.
• Storage: Store at room temperature (15-30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed and out of the reach and sight of children.
• Lifestyle: To reduce the risk of infection, maintain good hygiene, avoid contact with people who have active infections, and ensure all recommended vaccinations (including influenza and pneumococcal vaccines) are up to date before starting therapy. Avoid alcohol abuse; liver function may need to be monitored. If you are scheduled for surgery, inform your surgeon that you are taking baricitinib; the medication may need to be temporarily interrupted. Women of childbearing potential must use effective contraception during and for at least 1 week after treatment.
• When to seek medical review: Contact your doctor immediately if you develop signs of an infection (fever, cough, night sweats, persistent sore throat), symptoms of a blood clot (sudden leg pain or swelling, chest pain, shortness of breath), signs of liver problems (jaundice, dark urine, severe abdominal pain), or unusual bleeding or bruising. Seek emergency medical attention for severe allergic reactions (swelling of the face, tongue, or throat, difficulty breathing) or signs of a heart attack or stroke.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other JAK inhibitors: Upadacitinib (Rinvoq®) and tofacitinib (Xeljanz®) are alternatives for rheumatoid arthritis, atopic dermatitis, and other inflammatory conditions. Upadacitinib has a different JAK selectivity profile (JAK1 > JAK2) and is approved for similar indications, while tofacitinib is approved for RA, psoriatic arthritis, and ulcerative colitis. All JAK inhibitors carry the boxed warnings for serious infections, mortality, malignancies, MACE, and thrombosis.
• Biologic DMARDs: TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 receptor inhibitors (tocilizumab), and other biologics are first-line treatments for moderate to severe RA when conventional DMARDs fail. For atopic dermatitis, dupilumab (Dupixent®) is a biologic that targets the IL-4/IL-13 pathway and is often used before or in combination with baricitinib. For alopecia areata, oral minoxidil and other immunomodulators are sometimes used, but baricitinib is the first approved systemic therapy for severe disease.
• Conventional DMARDs: Methotrexate, sulfasalazine, and hydroxychloroquine remain the initial therapies for rheumatoid arthritis, often before biologics or JAK inhibitors are considered.
• Topical therapies for atopic dermatitis: Corticosteroids, calcineurin inhibitors (tacrolimus, pimecrolimus), and crisaborole are first-line for mild disease and are used as adjuncts to systemic therapy in moderate to severe cases.
• Non-pharmacological approaches: Physical therapy, occupational therapy, and lifestyle modifications (weight management, smoking cessation) are essential components of RA management. For atopic dermatitis, emollients, gentle skin care, and avoidance of triggers are critical.

Clinical Efficacy

The efficacy of baricitinib has been demonstrated in multiple Phase III clinical trials for rheumatoid arthritis, atopic dermatitis, and alopecia areata. In RA, the RA-BEAM and RA-BUILD trials showed that baricitinib 4 mg once daily, alone or with methotrexate, produced significant improvements in American College of Rheumatology 20% (ACR20) response rates (about 70% of patients) and Disease Activity Score 28 (DAS28) remission compared with placebo or adalimumab. In atopic dermatitis, the BREEZE-AD1 and BREEZE-AD2 trials demonstrated that baricitinib 4 mg achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) in approximately 16-21% of patients at week 16, with significant itch reduction as early as week 1. For severe alopecia areata, the BRAVE-AA1 and BRAVE-AA2 trials showed that baricitinib 4 mg resulted in clinically meaningful scalp hair regrowth (SALT score ≤ 20) in about 36% of patients at week 36, compared with 3-5% for placebo. Baricitinib’s safety profile includes increased risks of serious infections, venous thromboembolism, and cardiovascular events, particularly in older patients with multiple cardiovascular risk factors. Health Canada requires a boxed warning highlighting these risks. The 4 mg dose is the standard therapeutic strength across all approved indications, and the drug is recommended as an option for patients who have had an inadequate response to conventional therapies.

Important:

Olumiant (baricitinib) is a prescription medication that should be used only under the supervision of a qualified healthcare professional experienced in the management of inflammatory and autoimmune conditions. It carries a boxed warning for an increased risk of serious infections, major adverse cardiovascular events, malignancy, and venous thromboembolism. You should not take Olumiant if you have an active, serious infection, severe liver or kidney disease, or if you are pregnant or breastfeeding. Before starting therapy, you must be screened for tuberculosis and have blood tests to check your blood cell counts, liver function, and cholesterol. Regular blood monitoring is required throughout treatment. Live vaccines should not be given during therapy. If you develop signs of an infection, a blood clot, chest pain, or stroke symptoms, stop taking Olumiant and seek emergency medical attention immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Olumiant - Shipping across Canada